Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...
Black gay men face major PrEP access gaps due to cost, stigma, mistrust, and provider silence—despite high HIV impact; ...
Hosted on MSN
Monthly PrEP drug candidate shows promise
A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...
Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...
The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed that ...
By a News Reporter-Staff News Editor at CDC& FDA Daily-- Current study results on health insurance have been published. Our news reporters obtained a quote from the research from National Center for ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
A patient recently asked me this during his visit to an HIV clinic in the Dominican Republic. He was there to refill his monthly prescription for pre-exposure prophylaxis (PrEP), a daily pill that ...
In this Oct. 7, 2019, file photo, a pharmacist displays the HIV prevention drugs Descovy, left and Truvada, right, at a pharmacy in Sacramento, Calif. A proposed federal policy aims to protect older ...
Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results